Analysis of aspirin-associated risks in healthy individuals

Annals of Pharmacotherapy

Volumn 39, Issue 1, 2005, Pages 51-57

  Hur, Chin ^a,b   Simon, Lee S ^a,c   Gazelle, G Scott ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Aspirin; Chemoprevention; Risk analysis

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COMPUTER PROGRAM; CONTROLLED STUDY; DEATH; DECISION MAKING; DOSE RESPONSE; DRUG USE; DRUG WITHDRAWAL; ENTERIC COATED TABLET; EPISTAXIS; FEMALE; FOLLOW UP; GENDER; HEALTH CARE COST; HEALTH STATUS; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SOCIETY; STROKE; UPPER GASTROINTESTINAL BLEEDING; UROGENITAL TRACT DISEASE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 11144247022     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E115     Document Type: Article

References (45)

1. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
2. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, et al. Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the Task Force on Risk Reduction. American Heart Association Science Advisory and Coordinating Committee. Circulation 1997;95:2329-31.
3. U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002;136:157-60.
4. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322-7.
5. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90.
6. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
7. Imperiale TF. Aspirin and the prevention of colorectal cancer. N Engl J Med 2003;348:879-80.
8. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161-72.
9. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276:1172-7.
10. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001;85:265-71.
11. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-35.
12. Wolf PA, D'Agostino RB. Secular trends in stroke in the Framingham Study. Ann Epidemiol 1993;3:471-5.
13. Naglie IG, Detsky AS. Treatment of chronic nonvalvular atrial fibrillation in the elderly: a decision analysis. Med Decis Making 1992;12:239-49.
14. Centers for Medicare and Medicaid Services
15. Augustovski FA, Cantor SB, Thach CT, Spann SJ. Aspirin for primary prevention of cardiovascular events. J Gen Intern Med 1998;13:824-35.
16. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995;274:1839-45.
17. Drug topics red book. Montvale, NJ: Medical Economics, 2000.
18. Edelson JT, Tosteson AN, Sax P. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding. JAMA 1990;264:41-7.
19. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594-606.
20. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke 1996;27:1459-66.
21. National Compensation Survey. Washington, DC: Department of Labor, Bureau of Labor Statistics, 2003:Summary 04-03.
22. Thrombosis Prevention Trial: randomised trial of low-intensity oral anti-coagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998; 351:233-41.
23. U.S. Life tables: National vital statistics report: National Center for Health Statistics, 1997:10.
24. Fryback DG, Dasbach FJ, Klein R, Klein BE, Dorn N, Peterson K, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993;13:89-102.
25. Consumer Price Index, Medical Care Component. Washington, DC: Department of Labor, Bureau of Labor Statistics Data, 2003.
26. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276:1253-8.
27. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-73.
28. Gale EA. Lessons from the glitazones: a story of drug development. Lancet 2001;357:1870-5.
29. Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001;96:1698-703.
30. Smalley W, Shatin D, Wysowski DK, Gurwitz J, Andrade SE, Goodman M, et al. Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action. JAMA 2000;284:3036-9.
31. Modan B, Segal S, Shani M, Sheba C. Aplastic anemia in Israel: evaluation of the etiological role of chloramphenicol on a community-wide basis. Am J Med Sci 1975;270:441-5.
32. Lindquist M, Edwards IR. Risks of non-sedating antihistamines. Lancet 1997;349:1322.
33. Parvizi J, Johnson BG, Rowland C, Ereth MH, Lewallen DG. Thirty-day mortality after elective total hip arthroplasty. J Bone Joint Surg Am 2001;83-A:1524-8.
34. Chandrasekar B, Doucet S, Bilodeau L, Crepeau J, deGuise P, Gregoire J, et al. Complications of cardiac catheterization in the current era: a single-center experience. Catheter Cardiovasc Interv 2001;52:289-95.
35. Hallan S, Molaug PO, Arnulf V, Gisvold SE. [Causes and risk factors of intraoperative anesthesia complications. A prospective study of 14,735 anesthesias]. Tidsskr Nor Laegeforen 1990;110:38-41.
36. Tran DQ, Rosen L, Kim R, Riether RD, Stasik JJ, Khubchandani IT. Actual colonoscopy: what are the risks of perforation? Am Surg 2001; 67:845-7.
37. Lasser EC, Lyon SG, Berry CC. Reports on contrast media reactions: analysis of data from reports to the U.S. Food and Drug Administration. Radiology 1997;203:605-10.
38. Kemper AR, Davis MM, Freed GL. Expected adverse events in a mass smallpox vaccination campaign. Eff Clin Pract 2002;5:84-90.
39. Centers for Disease Control and Prevention
40. United States Parachute Association
41. Cohen JT, Graham JD. A revised economic analysis of restrictions on the use of cell phones while driving. Risk Anal 2003;23:5-17.
42. Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 2002;22:417-30.
43. Prentice RL. The analysis of failure times in the presence of competing risks. Biometrics 1978;34:541-54.
44. National vital statistics report. Atlanta: Centers for Disease Control and Prevention, 2001.
45. Lauer MS. Clinical practice. Aspirin for primary prevention of coronary events. N Engl J Med 2002;346:1468-74.